ArticleMycopathologia2016
Micafungin Elicits an Immunomodulatory Effect in Galleria mellonella and Mice.
Article in Mycopathologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Review
- Evaluation of the Ca37 Monoclonal Antibody Targeting Alcohol Dehydrogenase AgainstJournal of fungi (Basel, Switzerland) · 2025Article
- A new PK/PD target for assessing efficacy of micafungin against Candida parapsilosis.The Journal of antimicrobial chemotherapy · 2024Article
- Efficacy of LAMB against Emerging Azole- and Multidrug-ResistantJournal of fungi (Basel, Switzerland) · 2020Article
- Quantitative proteomic reveals gallium maltolate induces an iron-limited stress response and reduced quorum-sensing in Pseudomonas aeruginosa.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2020Article
- Review
- Article
- Antifungal Drugs Influence Neutrophil Effector Functions.Antimicrobial agents and chemotherapy · 2019Article
- Antifungal Activity, Toxicity, and Membranolytic Action of a Mastoparan Analog Peptide.Frontiers in cellular and infection microbiology · 2019Article
- Immune Response ofJournal of fungi (Basel, Switzerland) · 2018Review
- The Use ofJournal of fungi (Basel, Switzerland) · 2018Review
- Standardization ofJournal of fungi (Basel, Switzerland) · 2018Review
- Effect of Lactobacillus rhamnosus on the response of Galleria mellonella against Staphylococcus aureus and Escherichia coli infections.Archives of microbiology · 2018Article
- Of mice and men and larvae: Galleria mellonella to model the early host-pathogen interactions after fungal infection.Virulence · 2018Article
- An Update onFrontiers in microbiology · 2017Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
The echinocandin family of drugs is well characterized for antifungal function that inhibits β-D-glucan synthesis. The aim of this work was to study whether micafungin, a member of the echinocandin family, elicits additional activities that prime the host's immune response. We found that in a Galleria mellonella model, prophylactic treatment with micafungin extended the life of Staphylococcus aureus-infected larvae (a pathogen to which the drug demonstrates no direct antimicrobial activity) compared to insects that did not receive micafungin (P < 0.05). The inhibition of pathogens in the G. mellonella infection model was characterized by a 2.43-fold increase in hemocyte density, compared to larvae inoculated with PBS. In a murine model where animals were provided micafungin prophylaxis 3 days prior to macrophage collection, macrophages were found associated with an average 0.9 more fungal cells per macrophage as compared to saline-treated animals. Interestingly, micafungin-stimulated macrophages killed 11.6 ± 6.2 % of fungal cells compared to 3.8 ± 2.4 % of macrophages from saline-treated animals. The prophylactic provision of micafungin prior to Candida albicans infection was characterized by an increase in the proinflammatory cytokines CXCL13 and SPP1 by 11- and 6.9-fold, respectively. In conclusion, micafungin demonstrated the ability to stimulate phagocytic cells and promote an immune response that can inhibit microbial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.